ThromboGenics NV regains rights to Jetrea (ocriplasmin), a treatment for vitreomacular adhesion and vitreomacular traction, from Novartis.
ThromboGenics NV a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, announced that it will regain full global rights to Jetrea (ocriplasmin) from Alcon, a Novartis company, based on a mutual agreement that the unique characteristics of Jetrea make Thrombogenics a better fit for building a sustainable long-term niche business.
Jetrea is the first and only approved pharmacological treatment for symptomatic vitreomacular adhesion (VMA) in the US and vitreomacular traction (VMT) in Europe and elsewhere in the world. First introduced in 2013, Jetrea has been approved in 54 countries worldwide, with nearly 30,000 patients being treated in about 20 countries.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins